We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
206 result(s) found, displaying 31 to 40
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: lanadelumab.
-
Australian public assessment report (AusPar)Adcetris (brentuximab vedotin) has been approved for the treatment of Hodgkin lymphoma in patients with previously untreated CD30+ Stage III or Stage IV Hodgkin lymphoma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Medication transfer set.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Subcutaneous/intramuscular injection set, medicated.
-
Prescription medicine registrationActive ingredients: Brentuximab vedotin.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 2 TAKEDA, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack.